Breast Cancer

Latest News
April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

March 27th 2025

Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

February 18th 2025

Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 17th 2025

Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

February 13th 2025

TILs May Guide Treatment De-Escalation in ERBB2-Positive Breast Cancer

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
Video Interviews
View All
April 14th 2025

Investigators Advocate for Ongoing Comparison of Cancer Outcomes Among MA, FFS Beneficiaries

April 12th 2025

No Significant Differences Found in Breast Cancer Treatment Between MA, FFS Beneficiaries: Galen Shearn-Nance, BS

April 10th 2025

Mixed Outcomes Persist Between MA, FFS Beneficiaries: Johnie Rose, MD, PhD

February 21st 2025

Collaborative Approaches Provide Comprehensive Support in Cancer Care

February 20th 2025

TROPION-Breast01: The Evolving Role of TROP2-Directed ADCs in Breast Cancer

February 14th 2025

TROPION-Breast01: Datopotamab Deruxtecan Improves Progression-Free Survival

February 3rd 2025

Advancing Triple-Negative Breast Cancer Research in the Asia-Pacific Region

January 27th 2025

The Current State of Triple-Negative Breast Cancer Trials

January 16th 2025

Innovations in Breast Cancer Treatment With Dr Dawn Klemow

December 23rd 2024

Leveraging AI to Reduce Breast Cancer Risk

Podcasts
View All
October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

October 6th 2020

Living Life With Metastatic Breast Cancer From a Male Perspective

More News

Breast cancer - Crystal light - stock.adobe.com
February 11th 2025

Rising Breast Cancer Rates Show Disparities Across Racial, Ethnic Groups in the US

Pearl Steinzor
Significant increases in breast cancer incidence were found among Hispanic, American Indian or Alaska Native, and Asian or Pacific Islander women.
Breast cancer research. | Image Credit: Chinnapong - stock.adobe.com
February 5th 2025

How Socioeconomic Factors Shaped Responses to USPSTF Mammography Guidelines

Pearl Steinzor
Breast cancer screening rates shifted after the 2009 US Preventive Services Task Force (USPSTF) guidelines, with disparities emerging across race, income, and lifestyle factors.
antibody test | Image credit: angellodeco - stock.adobe.com
January 31st 2025

FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility

Pearl Steinzor
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted therapy.
Cancer cells targeted with immunotherapy. | Image credit: Jennifer - stock.adobe.com
January 30th 2025

Atezolizumab Fails to Help in High-Risk Triple-Negative Breast Cancer

Pearl Steinzor
Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.
FDA approved. | Image Credit: Pawel - stock.adobe.com
January 28th 2025

FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer

Pearl Steinzor
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
FDA approval | Image Credit: BHM - stock.adobe.com
January 17th 2025

FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer

Pearl Steinzor
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
Marie-France Jilderda, MD, PhD Candidate Surgical Oncology at Leiden University Medical Center in the Netherlands.
January 15th 2025

BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer

Cameron Santoro
The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Marie-France Jilderda, MD, PhD Candidate Surgical Oncology at Leiden University Medical Center in the Netherlands.
January 13th 2025

Identifying Patients With Low-Risk Breast Cancer for De-escalated Therapy

Cameron Santoro
A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially benefit from shorter or less-intensive treatment.
Elinzanetant | Image credit: Basstock - stock.adobe.com
January 9th 2025

Elinzanetant Excels in Phase 3 Study for Vasomotor Symptom Relief

Pearl Steinzor
Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in patients with hormone receptor–positive breast cancer.
Breast cancer research. | Image Credit: Chinnapong - stock.adobe.com
January 8th 2025

Impact of Sexual Counseling on Women With Breast Cancer

Pearl Steinzor
Self-efficacy–based sexual counseling may improve sexual function among breast cancer survivors, study finds.
Vivek H. Murthy, MD, MBA | Image Credit: © HHS
January 6th 2025

Alcohol and Cancer: Murthy’s Urgent Call

Maggie L. Shaw
Alcohol was first identified as a carcinogen almost 40 years ago, by the World Health Organization's International Agency for Research on Cancer.
Roberto Salgado, MD.
December 21st 2024

TILs: A Decade of Research Shapes Global Standards for Breast Cancer

Cameron Santoro Kennedy Ferruggia
Roberto Salgado, MD, anatomic pathologist for breast cancer translational research at Institut Jules Bordet, examines the significance of tumor-infiltrating lymphocytes (TILs) in various breast cancer types and emphasizes the need for standardized TIL evaluation methods to improve patient outcomes.
Top 5 Most-Read Breast Cancer Articles of 2024
December 17th 2024

Top 5 Most-Read Breast Cancer Articles of 2024

Cameron Santoro
The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as well as treatment outcomes.
Patients with breast cancer | Image Credit: ST.art - stock.adobe.com
December 12th 2024

Race and Immune Microenvironment Impacts on Breast Cancer Outcomes

Cameron Santoro
Breast cancer outcomes are significantly impacted by race and immune responses, particularly among Black patients with triple-negative subtypes, emphasizing the need to understand these disparities and develop more effective treatment strategies.
Breast cancer research. | Image Credit: Chinnapong - stock.adobe.com
December 11th 2024

Elacestrant Shows Real-World Effectiveness in Metastatic Breast Cancers

Cameron Santoro
Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.
Komal Jhaveri, MD, FACP.
December 11th 2024

EMBER-3 Trial: Imlunestrant Plus Abemaciclib Improves Survival in Advanced Breast Cancer

Cameron Santoro Kennedy Ferruggia
Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, presents findings from the EMBER-3 trial evaluating imlunestrant for patients with advanced breast cancer.
Patient takes medication. | Image Credit: sitthiphong - stock.adobe.com
November 29th 2024

Elacestrant Shows Significant PFS Benefit in ESR1-Mutated Metastatic Breast Cancer

Cameron Santoro
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) compared with standard-of-care treatments for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.
Young woman receiving breast screening | Image Credit: My Ocean studio - stock.adobe.com
November 23rd 2024

Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer

Cameron Santoro
Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.
Mei Wei, MD.
November 21st 2024

Targeted Therapies, Genomic Profiling Revolutionize Breast Cancer Treatment

Cameron Santoro
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses the latest advancements in HR+/HER2– breast cancer research, as well as the increasing role of genomic profiling in tailoring treatment plans.
Health equity text | Image Credit: Andrii - stock.adobe.com
November 19th 2024

Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

Cameron Santoro
Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.
Mabel Mardones, MD.
November 11th 2024

Future Breast Cancer Treatments: A Focus on SERDs, Biomarkers

Cameron Santoro
Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SERDs to improve patient outcomes.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
November 6th 2024

Breast Cancer Challenges and Promises in Immunotherapy

Cameron Santoro
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, particularly regarding immune-related adverse events.
Medicare Expansion | Image Credit: wladimir1804- stock.adobe.com
October 24th 2024

Breast Cancer Outcomes Improved in States With Medicaid Expansion

Cameron Santoro
Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.
Mabel Mardones, MD.
October 22nd 2024

Improving Access and Outcomes in HR+/HER2– Breast Cancer Treatment

Cameron Santoro
Mabel Mardones, MD, board-certified medical oncologist and hematologist who specializes in breast cancer at Rocky Mountain Cancer Centers, emphasizes the importance in identifying patients with HR-positive, HER2-negative (HR+/HER2–) breast cancer with unmet treatment needs.
Mei Wei, MD.
October 21st 2024

Rise of Innovative Therapies for Breast Cancer Treatment

Cameron Santoro
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and antibody-drug conjugates as promising alternatives to traditional therapies.
FDA Approved
October 11th 2024

FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

Julia Bonavitacola
Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after recurrence or completing adjuvant endocrine therapy.
Breast screening | Image Credit: Valerii Apetroaiei - stock.adobe.com
October 11th 2024

5 Things to Know Before a Breast Screening

Cameron Santoro
Here are 5 key points for pre–breast screening preparation that cover the areas of risk assessment, lifestyle adjustments, understanding screening details, managing anxiety, and open provider communication.
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
October 10th 2024

Advancing Breast Cancer Care With HER2-Targeted Therapies

Maggie L. Shaw
In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.
Breastcancergeneticrisk | Image Credit: © Rasi-stock.adobe.com
October 7th 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk

Maggie L. Shaw
Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.
Breast cancer support group | Image Credit: Atstock Productions - stock.adobe.com
October 1st 2024

ACS 2024 Report Shows Breast Cancer Equity Gap

Cameron Santoro
The American Cancer Society (ACS) 2024 report emphasizes significant racial disparities in breast cancer outcomes and calls for increased efforts to improve equity in screening and treatment.
12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo